NasdaqGM:SEPN 1 Year Share Price vs Fair Value Explore Septerna's Fair Values from the Community and select ...

Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway ...

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Investing.com -- Septerna, Inc. (NASDAQ: SEPN ), a biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, saw its shares fall 4.3% after reporting a widened net loss for ...

Septerna, Inc. ( ($SEPN) ) has released its Q2 earnings. Here is a breakdown of the information Septerna, Inc. presented to its investors.

Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

Septerna Inc. is listed on the CBOE trading with ticker code SEPN.US. It has a market capitalisation of $616.24m, with approximately 44.56m shares in issue. Over the last year, Septerna Inc. share ...